Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma Meeting Abstract
| Authors: | Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Dairiki, R.; Sachdev, P.; Dutcus, C. E.; Funahashi, Y.; Voss, M. H. |
| Abstract Title: | Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy269.074 |
| Language: | English |
| ACCESSION: | WOS:000459277300076 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy269.074 |
| Notes: | Meeting Abstract: 76P -- Appears on page viii23 of the abstract book -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work